ROCKVILLE, Md., April 29, 2024 (Globe Newswire) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) today entered into an agreement to sell commercial customer contracts and an installed base. announced that it had been concluded. He transferred the Unyvero system to Camtech Pte Ltd (“Camtech”), a family office in Singapore, for $218,000. The transaction follows Camtech's prior acquisition of all of the assets, rights and operations of Curetis' subsidiary, Curetis GmhH (“Curetis”), Unyvero, as part of Curetis' bankruptcy proceedings.
In addition, our subsidiary Ares Genetics GmbH sold all of its assets, including the ARESdb database and intellectual property portfolio, to bioMerieux SA as part of Ares Genetics' bankruptcy proceedings. The asset sales of both Curtis and Ares Genetics occurred as part of their bankruptcy proceedings, and OpGen is not involved in, and has no involvement in, such transactions.
OpGen will be working with the Camtech and Curtis teams over the coming months to relocate and transition U.S. Unyvero customers and operations. OpGen also offered Camtech the opportunity to acquire its remaining inventory of Unyvero systems for up to an additional $176,000. OpGen will maintain commercial operations and service support for his Unyvero systems until the remaining inventory is sold.
David Lazar, Chairman and CEO of Opgen, commented: “These transactions are consistent with our strategy to prepare Opgen for potential strategic transactions, including the potential reverse merger of private companies into Opgen. We believe this represents an attractive proposition for Opgen shareholders who could benefit from future value growth.”
About Opgen Co., Ltd.
OpGen, Inc. (Rockville, Maryland, USA) is a precision medicine company that harnesses the power of molecular diagnostics and bioinformatics to help fight infectious diseases. The company aims to provide clinicians with faster, actionable information about life-threatening infections to improve patient outcomes and reduce the spread of infections caused by multidrug-resistant organisms (MDROs). We distribute useful molecular microbiology solutions.
Learn more about. www.opgen.com
Forward-looking statements
This press release contains statements regarding the sale of certain assets and the sale of assets by our subsidiaries as part of bankruptcy proceedings. These statements and other statements regarding OpGen's future plans and objectives constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are subject to security measures. It is intended to be targeted. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond our control and may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those stated include our ability to regain compliance with Nasdaq listing rules, our ability to continue financing our business and operations, our liquidity and operational These include, but are not limited to, capital requirements. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please see the company's filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements because they are based on our expectations as of the date of this press release and speak only as of the date of this press release. Please be careful. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Opgene:
David E. Lazar
CEO
InvestorRelations@opgen.com
